The first in a new class of cancer medicines, Pfizer's Ibrance (EYE'-branse), appears poised for approval to treat advanced breast cancer within just a few months and could quickly become a blockbuster, some analysts believe.Fox Business...
BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (Biologic) Oncology Product Enhancement Biologic Phase 1 PF-06414300 project advanced Ulcerative Colitis Inflammation & Immunology New Molecular Entity Small Molecule Phase 1 PF-06835375 Lupus (Biologic) Inflammation & Immunology Product Enhancement Biolo...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for patients who are ...
Instead of testing one drug at a time, a novel lung cancer study announced on Thursday will allow British researchers to test up to 14 drugs from AstraZeneca and Pfizer at the same time within one trial.The aim is to quickly pinpoint medicines that can fight advanced lung cancer by targeti...
Nebulized lidocaine is the drug of choice for severe steroid-dependent asthma. Am. Coll. Allergy Asthma Immunol. Ann. Mtg A50 (2001). Barclay, L. New medical therapy briefs: irritable bowel syndrome [online], <http://www.centerwatch.com/bookstore/nmt/nmtb_ibs.pdf< (2004). Pfizer...
Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for patients with metastatic non-small cell lung cancer (NSCLC) w...
Merck tried again to reimburse Tepmetco for "locally advanced or metastatic non-small cell lung cancer with confirmed MET exon 14 skipping" but was not approved for reimbursement. Tepmetco, a MET inhibitor approved by the Ministry of Food and Drug Safety (MFDS) in November 2021, failed to ge...
Further, elranatamab (Elrexfio; Pfizer) is another BCMA-targeted drug with strong responses for patients. Callander said that patients who were in the groups that achieved complete responses (CRs) or very good partial responses (VGPRs) have yet to meet progression-free survival (PFS). Alterna...
A. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat. Rev. Drug Discov. 20, 551–569 (2021). CAS PubMed PubMed Central Google Scholar Crystal, A. S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer...
Firstly, four COVID-19 vaccines were authorized for use in Europe as of December 2020, listed below: the COVID-19 mRNA vaccines Comirnaty (developed by Pfizer/Biontech), Spikevax (formerly COVID-19 Vaccine Moderna), viral vector vaccines COVID-19 vaccine Janssen and Vaxzevria (formerly CO...